Opdivo Plus Chemotherapy Approved for First-Line Treatment of Gastric Cancer
The Food and Drug Administration (FDA) has approved Opdivo® (nivolumab; Bristol Myers Squibb), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The approval was based on data from the multicenter, randomized, open-label phase 3 CheckMate-649 trial (ClinicalTrials.gov: NCT02872116),…
